INBX
Inhibrx Biosciences, Inc.
NASDAQ: INBX · HEALTHCARE · BIOTECHNOLOGY
$127.58
-4.65% today
Updated 2026-06-05
Market cap
$1.53B
P/E ratio
—
P/S ratio
1,173.81x
EPS (TTM)
$-8.39
Dividend yield
—
52W range
$13 – $155
Volume
0.5M
Inhibrx Biosciences, Inc. (INBX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$127.58
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$49.96
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: -36.72% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.